Logo wahanariau.com
  2. Recursion pharmaceuticals

Recursion pharmaceuticals

Index
Globenewswire

Recursion and Exscientia, Two Leaders in the AI Drug Discovery Space, Have Officially Combined to Advance the Industrialization of Drug Discovery

Rabu, 20 November 2024 - 19:30:00 Wib
Globenewswire

Recursion Announces First Patient Dosed in Phase 2 Clinical Study of REC-3964, a Potential First-in-class, Oral, Non-antibiotic Small Molecule for Recurrent Clostridioides Difficile Infection

Selasa, 22 Oktober 2024 - 19:30:00 Wib
Globenewswire

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

Rabu, 02 Oktober 2024 - 19:30:00 Wib
Globenewswire

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

Selasa, 03 September 2024 - 19:30:00 Wib
Globenewswire

Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities

Kamis, 08 Agustus 2024 - 19:00:00 Wib
Globenewswire

Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer

Rabu, 17 April 2024 - 05:36:47 Wib
Globenewswire

Recursion Announces Plans to Open New Office in London

Senin, 11 Maret 2024 - 15:21:34 Wib
Globenewswire

Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery Pipeline

Kamis, 04 Januari 2024 - 20:00:00 Wib
Globenewswire

Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision Oncology

Kamis, 09 November 2023 - 22:34:00 Wib
Globenewswire

Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery

Rabu, 12 Juli 2023 - 22:01:00 Wib